TSHA - Taysha Gene Therapies GAAP EPS of -$0.10 beats by $0.01 revenue of $3.41M beats by $0.85M
2024-05-14 16:10:06 ET
More on Taysha Gene Therapies
- Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
- Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
- Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Taysha Gene Therapies upgraded at Jefferies on Rett Syndrome asset
- Taysha Gene Therapies Q1 2024 Earnings Preview